(Q41502331)

1 October 2017

1 reference

title

Review of immunosuppression for lung transplantation. Novel drugs, new uses for conventional immunosuppressants, and alternative strategies (English)

1 reference

1 October 2017

1 reference

1 reference

Hausen B

1

1 reference

PubMed ID

9187827

1 October 2017

Morris RE

series ordinal

2

1 reference

PubMed ID

9187827

1 October 2017

language of work or name

1 reference

1 June 1997

1 reference

Clinics in Chest Medicine

1 October 2017

1 reference

1 October 2017

18

1 reference

1 October 2017

2

1 reference

1 October 2017

353-366

1 reference

Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection

1 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity--I. Disease modifying action on adjuvant arthritis of the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Rapamycin for immunosuppression in organ allografting.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Prolongation of canine intestinal allograft survival with RS-61443, cyclosporine, and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Pulmonary transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Functional and histopathologic effects of rapamycin on mouse kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

The effect of rapamycin on kidney function in the Sprague-Dawley rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Total lymphoid irradiation: a novel and successful therapy for resistant cardiac allograft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

T-lymphocytes from AIDS patients are unable to synthesize ribonucleotides de novo in response to mitogenic stimulation. Impaired pyrimidine responses are already evident at early stages of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Efficacy of rapamycin and FK 506 in prolonging rat hind limb allograft survival

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Rapamycin selectively blocks interleukin-2-induced proliferating cell nuclear antigen gene expression in T lymphocyte. Evidence for inhibition of CREB/ATF binding activities

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Chronic myelogenous leukemia after lymphoid irradiation and heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Total lymphoid irradiation in heart transplantation: adjunctive treatment for recurrent rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Dose study of the immunosuppression of FK 506 in canine lung allo-transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Long-term health status and quality of life outcomes of lung transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients--importance of trough level as a practical indicator

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Consensus document: therapeutic monitoring of tacrolimus (FK-506).

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

IMPROVED IMMUNOSUPPRESSION WITH AEROSOLIZED CYCLOSPORINE IN EXPERIMENTAL PULMONARY TRANSPLANTATION1

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Clinical trial of tacrolimus versus cyclosporine in lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Efficacy of inhaled cyclosporine in lung transplant recipients with refractory rejection: correlation of intragraft cytokine gene expression with pulmonary function and histologic characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Discovery of FK-506 and update

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Bioavailability improvement of mycophenolic acid through amino ester derivatization

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

FK506 and cyclosporin, molecular probes for studying intracellular signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Blood distribution and single-dose pharmacokinetics of leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Infectious complications following isolated lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Therapeutic drug monitoring of tacrolimus in clinical transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Immunosuppressive effect of mycophenolic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Comparison of FK-506, rapamycin, ascomycin, and cyclosporine in mouse models of host-versus-graft disease and heterotopic heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Tacrolimus for prevention of liver allograft rejection: clinical trials and tribulations

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Delivery and distribution of aerosolized cyclosporine in lung allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Purine and pyrimidine metabolism in peripheral blood lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

RS-61443--a new, potent immunosuppressive agent

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Mechanism of action of mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Obliterative bronchiolitis after lung and heart-lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Mycophenolate mofetil: a report of the consensus panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Regulation of B cell function by the immunosuppressive agent leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

RS-61443--a phase I clinical trial and pilot rescue study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Randomised trialomania? The multicentre liver transplant trials of tacrolimus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Toxicity of rapamycin--a comparative and combination study with cyclosporine at immunotherapeutic dosage in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

The mechanism of action of FK-506 and cyclosporin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Inhibition of Protein Tyrosine Phosphorylation in T Cells by a Novel Immunosuppressive Agent, Leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Measurement of rapamycin in whole blood using reverse-phase high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Immunosuppression with aerosolized cyclosporine for prevention of lung rejection in a rat model

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

Leflunomide, a reversible inhibitor of pyrimidine biosynthesis?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970384-1

7 January 2021

10.1016/S0272-5231(05)70384-1

Identifiers

DOI

1 reference

1 October 2017

1 reference

PubMed ID

9187827